Extended Data Fig. 7: The antitumor activity αVHH CAR T cells is comparable to αHER2 CAR T cells against VHH + HER2+ tumors.
(a) Representative flow plots of HER2 and VHH expression on either wildtype or 468-HV tumor cells. Data is representative from a single experiment, repeated 2 times with similar results. (b) 468-HV tumor cells were cocultured with either human untransduced (UTD), αHER2 CAR, or αVHH CAR T cells at a 2:1 E:T ratio and assessed for cytotixicity after 24 hrs (Mean of n = 3 technical replicates) and (c) growth curves of 468-HV tumors following treatment with the UTD, αHER2 CAR, or αVHH CAR T cells. (Two-way ANOVA, mean ± s.e.m., n = 6 mice per cohort, αVHH (**p = 0.0080 on day 6, **p = 0.0015 on day 13, ***p = 0.0003 on day 18, ***p = 0.0005 on day 25, ***p = 0.0003 on day 33) and αHER2 (††p = 0.0054 on day 6, ††p = 0.0016 on day 13, †††p = 0.0003 on day 18, †††p = 0.0005 on day 25, †††p = 0.0003 on day 33) CAR T cell treatments are compared to UTD.
